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REPORT
Mutations in the Gene Encoding 3-Hydroxyisobutyryl-CoA
Hydrolase Results in Progressive Infantile Neurodegeneration
Ference J. Loupatty, Peter T. Clayton, Jos P. N. Ruiter, Rob Ofman, Lodewijk IJlst, Garry K. Brown,
David R. Thorburn, Robert A. Harris, Marinus Duran, Carlos DeSousa, Steve Krywawych,
Simon J. R. Heales, and Ronald J. A. Wanders
Only a single patient with 3-hydroxyisobutyryl-CoA hydrolase deficiency has been described in the literature, and the
molecular basis of this inborn error of valine catabolism has remained unknown until now. Here, we present a second
patient with 3-hydroxyisobutyryl-CoA hydrolase deficiency, who was identified through blood spot acylcarnitine analysis
showing persistently increased levels of hydroxy-C4-carnitine. Both patients manifested hypotonia, poor feeding, motor
delay, and subsequent neurological regression in infancy. Additional features in the newly identified patient included
episodes of ketoacidosis and Leigh-like changes in the basal ganglia on a magnetic resonance imaging scan. In cultured
skin fibroblasts from both patients, the 3-hydroxyisobutyryl-CoA hydrolase activity was deficient, and virtually no 3-
hydroxyisobutyryl-CoA hydrolase protein could be detected by western blotting. Molecular analysis in both patients
uncovered mutations in the HIBCH gene, including one missense mutation in a conserved part of the protein and two
mutations affecting splicing. A carefully interpreted acylcarnitine profile will allow more patients with 3-hydroxyiso-
butyryl-CoA hydrolase deficiency to be diagnosed.
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The catabolic pathway for the branched-chain amino
acid valine is believed to be exceptional because part of
the pathway between 3-hydroxyisobutyryl-CoA and pro-
pionyl-CoA proceeds via free acids, thus requiring a spe-
cific hydrolase. This is in marked contrast with the deg-
radation pathways of the other branched-chain amino
acids (i.e., leucine and isoleucine, in which the interme-
diates distal to the 2-oxo-acids are all CoA thioesters). In-
deed, the hydrolysis of an activated acyl group in the heart
of a catabolic pathway is not only uncommon but also
energetically unfavorable, especially when subsequent
steps of the pathway again involve CoA thioester inter-
mediates. Although the evidence for the need of a specific
hydrolase in the catabolic pathway of valine was poor,
strong support for this hypothesis nevertheless came from
one case report, published in 1982, documenting 3-hy-
droxyisobutyryl-CoA hydrolase (HIBCH) deficiency (MIM
250620).1 However, the molecular basis of HIBCH defi-
ciency has remained unknown.
Brown and colleagues1 described a male infant (patient
1), born to consanguineous parents, who clinically man-
ifested various physical malformations (dysmorphic facial
features, multiple vertebral anomalies, tetralogy of Fallot,
and—at post mortem examination—agenesis of the cin-
gulate gyrus and corpus callosum), as well as failure to
thrive and marked hypotonia. More importantly, how-
ever, the urine of this patient persistently demonstrated
increased levels of S-2-carboxypropyl-cysteamine and S-2-
carboxypropyl-cysteine.1,2 As the latter compound can be
formed by the condensation between cysteine and meth-
acrylyl-CoA, an intermediate in valine oxidation, the ab-
normal levels suggested a defect in the valine catabolic
pathway. In valine catabolism (fig. 1), methacrylyl-CoA is
converted to 3-hydroxyisobutyryl-CoA by crotonase, but
fibroblast and liver homogenates of patient 1 showed nor-
mal hydratase activities towards methacrylyl-CoA (as well
as crotonyl-CoA and tiglyl-CoA) when compared with
controls. This finding suggested that, if a defect in the
catabolic pathway of valine were to exist, it would be distal
to this hydration reaction. Indeed, through a coupled en-
zyme assay using methacrylyl-CoA and an excess of the
enzyme crotonase, Brown et al.1 demonstrated a 20% re-
sidual activity of HIBCH in cultured skin fibroblasts.1 No
additional patients with HIBCH deficiency have been re-
ported so far.
In this report, we describe a second patient with HIBCH
deficiency (patient 2), who was the first child of healthy,
nonconsanguineous white parents and was born at term
following an uneventful pregnancy. Initially, he fed poorly
but otherwise appeared well, until 4 mo of age, when his
parents noted head bobbing. This was followed by a delay
in motor milestones and then by ataxia and a loss of skills.
He was able to roll over at age 5 mo but lost this ability
at age 10 mo. He was reaching out and grasping objects
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Figure 1. Catabolism of L-valine. The names of the intermedi-
ates in the pathway for catabolism of L-valine are shown on the
left, with solid arrows indicating enzymatic reactions. The struc-
tures of methacrylyl-CoA, 3-hydroxyisubutyryl-CoA, and 3-hydrox-
yisobutyrate are depicted on the left. The names of the metabolites
that are increased as result of HIBCH deficiency are shown by
dashed arrows on the right.
Figure 2. MRI scans made when patient 2 was 14 mo old (T2-
weighted images). There is signal abnormality in the brain regions
indicated by the white arrows: in the globi pallidi (upper panel)
and in the midbrain with asymmetrical involvement of the cerebral
peduncles (RrL) (lower panel). The appearances were considered
likely to represent a neurometabolic disorder. No structural ab-
normality was noted.
at 4 mo but gradually lost this skill at 13 mo. From age 9
mo, he started to have transient absences and episodes of
eye rolling. At age 10 mo, he had a febrile illness, during
which he became irritable and more wobbly. He lost the
ability to finger feed. Examination at age 11 mo revealed
an alert, interactive child who had no nystagmus but con-
stant titubation of the head. He had marked truncal ataxia
and was unable to sit unsupported. Tone, power, and re-
flexes were normal in the upper limbs; tone was reduced,
particularly distally, in the lower limbs. He had marked
dysmetria and tremor on reaching out. At age 14 mo, fol-
lowing 2 d of coryza and lethargy, he became acutely un-
well, with a reduced level of consciousness and metabolic
acidosis, and required intubation and ventilatory support.
Blood pH was 7.29, with a base deficit of 15.8 mmol/L.
Blood lactate and ammonia levels were normal. Echocar-
diography demonstrated no anomalies. Examination fol-
lowing recovery from this illness showed drowsiness, var-
iable nystagmus, sluggish papillary responses, pooling of
secretions in the mouth, fasciculation of the tongue, tit-
ubation of the head, and upper- and lower-limb hypotonia
with preservation of reflexes. He showed no improvement
on treatment with thiamine or a combination of vitamin
C, vitamin E, and ubiquinone. As he recovered from his
episode of acute encephalopathy, he developed dystonia,
predominantly affecting the right arm and leg. A CT scan
performed during the episode of acute encephalopathy
revealed generalized edema of the brain, with loss of grey/
white differentiation in the basal ganglia. In addition, a
magnetic resonance imaging (MRI) scan (fig. 2) detected
signal abnormalities in the globus pallidus and the mid-
brain, with asymmetrical involvement of the cerebral pe-
duncles (right greater than left). No structural abnormal-
ities of the brain were observed.
As the neuroimaging was reminiscent of Leigh disease,
we investigated the activities of pyruvate dehydrogenase
and pyruvate carboxylase in cultured human skin fibro-
blasts and measured the activities of respiratory chain
complexes in a muscle biopsy of patient 2, as described
elsewhere.3–7 Normal activities were found for pyruvate
carboxylase and pyruvate dehydrogenase. The activities of
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Figure 3. Immunoblot analysis of HIBCH in fibroblast lysates
and human liver homogenates. 25 mg of human liver (HL) protein
and equal amounts of fibroblast protein (100 mg) of two control
subjects (C1 and C2), the index patient (P1), and the newly iden-
tified patient (P2) were subjected to SDS-PAGE and transferred
onto nitrocellulose by semidry blotting. Polyclonal antibodies
raised against purified rat liver HIBCH were used at a dilution of
1:5,000. Antigen-antibody complexes were visualized with goat
anti-rabbit IgG-alkaline phosphatase conjugate. As a control for
transfer of protein, each blot was reversibly stained with Ponceau
S before the incubation with antibodies.
the respiratory chain complexes, expressed as a ratio to
the activity of citrate synthase, revealed a marked reduc-
tion of complex I (patient 0.089, controls 0.104–0.268)
and a borderline reduction of complex IV (patient 0.013,
controls 0.014–0.034). These results were obtained on a
muscle biopsy sample obtained 3 mo after the major ep-
isode of metabolic decompensation. A second muscle bi-
opsy sample, obtained 3 mo later, showed normal activ-
ities of all four respiratory chain complexes. Urine organic
acid analysis during ketotic episodes showed excessive
excretion of 3-hydroxybutyrate and acetoacetate and
moderate excretion of lactate, 2-hydroxyisovalerate, 2-ox-
oisocaproate, dicarboxylic acids (C6, C8, C10), and meth-
ylmalonate, with normal levels of methylcitrate. In con-
trast, he excreted normal levels of urinary organic acids
when well. Normal values were found for nonfasting
blood 3-hydroxybutyrate (!0.05 mM) and for blood and
CSF lactate. Urine amino acid analysis showed normal re-
sults, except on one occasion, when it showed increased
ratios to creatinine of several amino acids (including gly-
cine, alanine, and taurine), as well as one unidentified
ninhydrin positive compound.
Remarkably, elevated levels of hydroxy-C4-carnitine
were consistently found in blood spots of patient 2. Its
concentration ranged from 0.45–1.73 mM, controls !0.4
mM. Elevation of hydroxy-C4-carnitine may occur in ke-
tosis, but the elevated blood concentration persisted in
this patient even when he was not ketotic. Tandem mass
spectrometric analysis does not distinguish between 3-hy-
droxy-n-butyryl-carnitine and 3-hydroxyisobutyryl-car-
nitine. Either of these hydroxy-C4-carnitine species could
be increased as a consequence of a specific enzyme defect,
such as short chain 3-hydroxyacyl-CoA dehydrogenasede-
ficiency (SCHAD [MIM 300256]) or HIBCH deficiency, re-
spectively. Patients with SCHAD deficiency uniformly suf-
fer from hyperinsulinism,8 a phenotype very different
from that observed in patient 2. As expected, a normal
activity of short chain 3-hydroxyacyl-CoA dehydrogenase
was found in the fibroblasts of this patient, as well as in
patient 1 (data not shown), suggesting HIBCH deficiency.
Therefore, we investigated fibroblasts of patients 1 and
2 for HIBCH activity, by use of a direct enzyme assay based
on the use of the physiological substrate S-3-hydroxy-
isobutyryl-CoA. The thioester was synthesized from
methyl S-3-hydroxyisobutyrate as described elsewhere.9,10
HIBCH activity was subsequently measured spectropho-
tometrically. The reaction mixture contained in a total
volume of 250 mL, 100 mM Tris.HCl pH 8.0, 1 mM EDTA,
1 g/L Triton X-100, 0.1 mM, DTNB and 0.2–0.4 mg/ml
fibroblast homogenate. After a preincubation period of 10
min, the reaction was started by the addition of 3-hy-
droxyisobutyryl-CoA at a final concentration of 0.2 mM.
The reduction of DTNB was followed in time on a Cobas-
Fara centrifugal analyzer (Roche) at 412 nm, with use of
a molar extinction coefficient of 13,700 L/mol/cm. By use
of this newly developed assay, a mean  SD activity of
6.4  1.6 nmol/min/mg protein was found in control
fibroblasts ( ), whereas, in fibroblasts from both pa-np 8
tients, no HIBCH activity could be detected.
A human cDNA (HIBCH) encoding a protein with
HIBCH activity has been described elsewhere.11 This
HIBCH gene maps to chromosome 2q32.2 and has an
ORF of 1,161 bp, encoding a protein of 386 aa residues
with a calculated molecular weight of 43 kDa. Immuno-
blot analysis, performed using an antibody against
HIBCH, revealed the absence of the HIBCH protein in pa-
tient 1 (fig. 3). Fibroblast lysates of patient 2 demonstrated
an apparently lower expression of the HIBCH protein than
was seen in controls.
To establish that HIBCH deficiency is caused by muta-
tions in HIBCH, we analyzed the gene at the genomic level
and the mRNA level in both patients. We identified a ho-
mozygous IVS3-9TrG mutation in patient 1, consistent
with parental consanguinity. The IVS3-9TrG mutation
was absent from 210 control chromosomes. However, this
TrG transversion only slightly weakens the consensus se-
quence for a splice acceptor site, since a pyrimidine is
preferred over a purine at this position in the consensus
sequence. Hence, the consequence of this missense mu-
tation on the splicing efficiency was investigated by anal-
ysis of HIBCH cDNA obtained by RT-PCR from skin fibro-
blast RNA. Sequence analysis of the amplicon revealed a
homozygous 8-bp insertion (c.219_220insTTGAATAG),af-
ter the last base of exon 3, causing a frameshift (K73fsX86).
The 8-bp insertion resulted from retention of the 3′ end
of intron 3. Close examination of the intronic DNA se-
quence adjacent to the IVS3-9TrG mutation revealed a
stronger homology to the consensus sequence of a splice
acceptor site than present in the wild-type intronic se-
quence, with identity at 9 of 10 intronic bases instead of
7 of 10 (fig. 4). Both the wild-type and mutant sequences
are preceded by a DNA sequence with strong homology
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Figure 4. Cryptic splice acceptor site in patient 1. A, Sequence analysis of the genomic DNA region from which the 8-bp insertion
originates and amplified by PCR from control subjects identified an intron of 2,183 bp (small lettering) with consensus splice donor–
and splice acceptor–site sequences (italics and underlined) and branch point (underlined). The complete nucleotide sequence of the
intron can be obtained from GenBank (accession number NT_005403). B, In patient 1, a TrG mutation (*) at the 9 position of the
authentic splice acceptor site (underlined) results in alternative splicing at a cryptic splice acceptor site located 9 bp 5′ of the authentic
splice acceptor site and preceded by a consensus branch point sequence. The 8-bp intron sequence, which is retained as a result of
the aberrant splicing, is indicated in bold. Original exon sequences are indicated in capitals. Consensus sequences are defined as follows:
splice donor site, [exon]..(C/A)AGfgt(a/g)agt..[intron]; branch point, (t/c)n(t/c)t(g/a)ac (18–40 bp 5′ of splice acceptor site); splice
acceptor site, [intron]..(t/c)6n(t/c)ag f G(G/T)..[exon].
to the branch point consensus sequence, thus constituting
a rather strong alternative cryptic splice acceptor site (fig.
4). Missplicing was evident, because only the aberrant
spliced transcript could be detected.
Sequence analysis revealed that patient 2 was com-
pound heterozygous for a missense mutation, c365ArG
(Y122C), and a splice acceptor site mutation, IVS2-3CrG.
The latter mutation was paternal, whereas the mother was
a heterozygous carrier of the c365ArG mutation. The mis-
sense mutation predicts the substitution of the bulky
amino acid residue tyrosine, which is conserved among
different species, including Mus musculus (mouse), Rattus
norvegicus (rat), Arabidopsis thaliana (plant), Caenorhabditis
elegans (nematode), Gallus gallus (chicken), Xenopus tro-
picalis (frog), Bos taurus (cow), Canis familiaris (dog), Pongo
pygmaeus (orangutan), Danio rerio (zebrafish), Saccharo-
myces cerevisiae (budding yeast) and Schizosaccharomyces
pombe (fission yeast). The IVS2-3CrG transversion dis-
rupts the consensus sequence for a splice acceptor site,
given that a pyrimidine (cytosine or thymine) is preferred
over guanine at this position in the consensus sequence.
Thus, the significance of this particular mutation on splic-
ing was investigated by analysis of HIBCH cDNA. Re-
markably, sequence analysis revealed a heterozygous 2-bp
insertion resulting from retention of the 3′ end of intron
2, causing a frameshift (R27fsX50). Indeed, the intronic
DNA sequence adjacent to the IVS2-3CrG mutation pre-
sented a strong homology to the consensus sequence of
a splice acceptor site, with identity at 9 of 10 intronic
bases. Because this sequence is preceded by a branch point
consensus sequence, it constitutes an alternative splice ac-
ceptor site. Compound heterozygosity for the Y122C and
the IVS2-3CrG mutations resulted in a complete absence
of HIBCH activity in the patient, indicative of a patho-
genetic effect of both mutations. However, to exclude that
the Y122C and the IVS2-3CrG mutations present poly-
morphic variants, we analyzed 210 control chromosomes
for both mutations, assuming a general polymorphic var-
iant frequency of 0.01, but we did not detect either of
these mutations. On the basis of these data, we conclude
that HIBCH deficiency is caused by mutations in the
HIBCH gene.
Until now, only one patient with HIBCH deficiency had
been described. The urine of this patient showed abnormal
levels of S-2-carboxypropyl-cysteine and S-2-carboxypro-
pyl-cysteamine, which were found using a combination
of high-voltage electrophoresis, paper chromatography,
and ninhydrin staining.2 However, in many present-day
laboratories, routine analysis of plasma and urinary amino
acids is performed by liquid chromatography using lith-
ium citrate buffers for elution.12 Unfortunately, S-2-car-
boxypropyl-cysteine was not available as a reference sub-
stance, which precluded a correct identification in patient
2. The concentration of S-2-carboxypropyl-cysteine and S-
2-carboxypropyl-cysteamine in patient 1’s urine2 was es-
timated to be !10 mM. Furthermore, S-2-carboxypropyl-
cysteine has a retention time close to those of glycine,
alanine, and citrulline.12 Because these amino acids are
commonly present in the urine of children, they can easily
obscure the presence of the cysteine adducts. As a con-
sequence, additional patients with HIBCH deficiency may
easily have remained undetected by this amino acid–an-
alyzer approach. This is exemplified by patient 2, in whom
only one out of four urine samples showed an unidentified
ninhydrin positive compound. However, we were unable
to determine if this compound was S-2-carboxypropyl-cys-
teine or S-2-carboxypropyl-cysteamine. Fortunately, it was
the detection of persistently elevated hydroxy-C4-carni-
tine in the blood of this patient that led us to determine
the activity of HIBCH.
Both patients with HIBCH deficiency demonstrated de-
layed development of motor skills, hypotonia, initial poor
feeding, and a deterioration in neurological function dur-
ing the first stages of life. However, the neuropathology
of patient 1 included agenesis of the cingulate gyrus and
the corpus callosum, whereas no structural brain abnor-
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malities were observed in patient 2. Moreover, the brain
anomalies of patient 2, as indicated on the CT and MRI
scans, were predominantly in the basal ganglia—as is com-
monly seen in respiratory chain disorders (Leigh disease),
glutaric aciduria type I, methylmalonic acidaemia, and
priopionic acidaemia. It is also important to note that, in
contrast with patient 1, patient 2 manifested no dys-
morphic (facial) features and no congenital heart disease
(tetralogy of Fallot) and is still alive today.
Treatment of patients with HIBCH deficiency should be
aimed at prevention of an increased flux through the cat-
abolic pathway of L-valine. Hence, it is advisable to reduce
the protein intake and maintain a high carbohydrate in-
take, especially during episodes of ketosis (as is done for
other disorders of branched chain amino acid catabolism).
Other possible therapeutic approaches include adminis-
tration of carnitine to release coenzyme A and increase
the elimination of 3-hydroxyisobutyryl-CoA as urinary 3-
hydroxyisobutyrylcarnitine, together with administration
of pantothenate (vitamin B5) to compensate for the fact
that at least part of intracellular CoA will be trapped in
the form 3-hydroxyisobutyryl-CoA.
In conclusion, we have resolved the molecular basis of
HIBCH deficiency. By doing so, we also provide conclusive
evidence that, in humans, part of the catabolic pathway
of valine does indeed proceed via free acids, in contrast
with the degradation of the other branched-chain amino
acids leucine and isoleucine. Furthermore, we have iden-
tified the second patient with HIBCH deficiency. Both pa-
tients with HIBCH deficiency demonstrated progressive
neurodegeneration. Our data suggest that analysis of
blood spot acylcarnitines may circumvent the problematic
analysis of the amino acids S-2-carboxypropyl-cysteine
and S-2-carboxypropyl-cysteamine, which previously led
to the diagnosis of HIBCH deficiency. Moreover, because
hydroxy-C4-carnitine could appear in routine acyl-carni-
tine analysis, we predict that more patients with HIBCH
deficiency will be diagnosed as this technique becomes
more widely available. Until we have more experience
with the natural history of this disorder and the effect of
therapeutic interventions, it is probably wise to regard
HIBCH deficiency as a disorder associated with progressive
neurological damage, ultimately leading to early death.
Fortunately, the full elucidation of the molecular and met-
abolic basis of the disorder will allow prenatal diagnosis.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for HIBCH
[accession numbers NT_005403])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/OMIM/
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